Semaglutide vs. Tirzepatide: The Molecule Comparison

The two active ingredients behind every GLP-1 product — branded and compounded. They work through different receptors, produce different outcomes, and have different side-effect profiles. Here's the detailed molecular breakdown.

Every GLP-1 product on the market — Ozempic, Wegovy, Mounjaro, Zepbound, and every compounded variant — is built on one of two molecules: semaglutide or tirzepatide. The branding matters less than which molecule you're actually taking. Understanding the difference helps you choose (and understand side effects, efficacy, and switching decisions).

The molecules themselves

Feature	Semaglutide	Tirzepatide
Receptor targets	GLP-1 only (mono-agonist)	GLP-1 AND GIP (dual agonist)
Brand names	Ozempic, Wegovy, Rybelsus	Mounjaro, Zepbound
FDA approval year	2017 (Ozempic)	2022 (Mounjaro)
Manufacturer	Novo Nordisk	Eli Lilly
Half-life	~1 week	~5 days
Avg weight loss (obesity trials)	~15%	~21%
Avg A1C reduction (T2D trials)	1.4–1.8%	1.9–2.4%

How they work

Semaglutide: the GLP-1 specialist

Semaglutide is a synthetic version of the human GLP-1 hormone, modified to resist rapid breakdown. It binds to GLP-1 receptors in the pancreas, brain, stomach, and elsewhere. The effects:

Pancreas: Stimulates insulin release when blood glucose is high; suppresses glucagon.
Stomach: Slows gastric emptying — food stays in your stomach longer, creating prolonged satiety.
Brain: Acts on hypothalamic appetite centers to reduce hunger signals.
Cardiovascular system: Independent effects on vascular health, including the CV risk reduction shown in SUSTAIN-6 and SELECT trials.

Tirzepatide: the dual agonist

Tirzepatide does everything semaglutide does, plus also binds to GIP (glucose-dependent insulinotropic polypeptide) receptors. GIP is another incretin hormone that works alongside GLP-1 in glucose metabolism. Adding GIP agonism produces:

Synergistic insulin release when combined with GLP-1 effects.
Enhanced lipolysis (fat breakdown) — potentially why tirzepatide produces greater fat-specific weight loss.
Improved insulin sensitivity beyond what GLP-1 alone achieves.
Different satiety signaling — some patients report longer-lasting appetite suppression.

Efficacy: what the trials show

Weight loss trials

Direct comparison data comes from SURMOUNT-5 and meta-analyses:

Semaglutide (STEP 1): 14.9% average weight loss at 68 weeks in non-diabetic obesity.
Tirzepatide (SURMOUNT-1): 20.9% average weight loss at 72 weeks in non-diabetic obesity (15mg dose).
Head-to-head (SURMOUNT-5): Tirzepatide significantly outperformed semaglutide across all measured timepoints.

Glycemic control (T2D)

Semaglutide (SUSTAIN trials): 1.4–1.8% A1C reduction at maintenance dose.
Tirzepatide (SURPASS trials): 1.9–2.4% A1C reduction — superior to semaglutide in SURPASS-2 head-to-head.

Cardiovascular outcomes

Semaglutide (SELECT trial): 20% reduction in major adverse CV events in overweight/obese patients with CVD.
Tirzepatide (SURMOUNT-MMO): CV outcomes trial ongoing; results not yet available.

This is semaglutide's one clear clinical advantage — it has definitive CV outcomes data and FDA-approved CV indication. Tirzepatide doesn't yet.

Side effects: similar but distinct

Both molecules share the GI-dominant side effect profile: nausea, vomiting, diarrhea, constipation, abdominal pain. The distribution differs slightly:

Semaglutide: Slightly higher rates of vomiting reported in trials.
Tirzepatide: Slightly higher rates of diarrhea reported.
Both: Rare risk of thyroid C-cell tumors in rodent studies (contraindicated in patients with personal/family history of medullary thyroid carcinoma or MEN 2).
Both: Pancreatitis warnings, though rare in clinical practice.
Both: Gallbladder issues (increased gallstone risk during rapid weight loss).

Individual tolerance varies dramatically. Some patients can't tolerate semaglutide but do well on tirzepatide (and vice versa). Switching is reasonable if one isn't working.

Which to start with

For most patients new to GLP-1s in 2026, tirzepatide is the clinical first-line choice based on:

Greater weight loss magnitude
Superior glycemic control in T2D
Dual mechanism provides more metabolic levers
Similar safety profile

Exceptions where semaglutide makes more sense:

Established cardiovascular disease (for CV risk reduction benefit)
Insurance covers semaglutide but not tirzepatide
Patient prioritizes longer safety track record
History of poor tolerance to tirzepatide specifically

The oral option comparison

Both molecules now have oral formulations:

Semaglutide: Rybelsus (diabetes, FDA-approved 2019), Oral Wegovy (weight loss, FDA-approved 2024).
Tirzepatide: Orforglipron (small-molecule GLP-1 agonist, not tirzepatide specifically — under FDA review from Lilly, expected 2026 launch).

Currently, if you want oral GLP-1 for weight loss, semaglutide (Oral Wegovy at $149/mo) is your only FDA-approved option. Compounded oral tirzepatide exists through platforms like Sprout Health but isn't FDA-approved.

Switching between them

Under provider supervision, switching from semaglutide to tirzepatide or vice versa is straightforward:

Semaglutide → Tirzepatide: Start tirzepatide at 2.5mg weekly regardless of prior semaglutide dose. Re-titrate from there.
Tirzepatide → Semaglutide: Start semaglutide at 0.25mg weekly regardless of prior tirzepatide dose. Re-titrate.
Compounded → Brand: Start at brand's lowest dose. Compounded dosing doesn't translate directly to branded pen doses.

Bottom line

For 2026, tirzepatide is the clinical front-runner for both weight loss and glycemic control. Semaglutide retains advantages in cardiovascular outcomes, oral formulation availability, and established safety data. For most patients without specific CV concerns, tirzepatide is reasonable first-line; semaglutide is reasonable second-line or first-line with CV indication. The molecules matter more than the brands — choose based on what your body responds to, not marketing.